Legend Biotech Corporation reported impressive first-quarter results for 2026, with CARVYKTI net trade sales reaching $597 million, a 52% increase year-over-year. This growth was fueled by a 36% rise in U.S. sales and over 200% growth outside the U.S., driven by expanding adoption in earlier treatment lines and robust manufacturing capabilities. The company achieved a 99% manufacturing success rate and a median turnaround time of 29 days, which supports its growing global footprint now encompassing 18 markets and 300 treatment sites.
The financial performance reflects a narrowing of adjusted net loss to $11 million, down from $27 million a year ago, despite a temporary dip in gross margins due to one-time manufacturing expenses. Management remains optimistic about achieving adjusted profitability in 2026, bolstered by a strong cash position of $835 million and no long-term debt. The ongoing enrollment in pivotal CARTITUDE trials further underscores the company’s commitment to advancing its pipeline.
For market professionals, the key takeaway is that Legend Biotech’s strong sales momentum and operational efficiency position it well for sustained growth, particularly as CARVYKTI gains traction in earlier treatment settings, potentially expanding its market share in the competitive CAR-T landscape.
Source: fool.com